Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone

NCT01257412 · clinicaltrials.gov ↗

PHASE3

Phase

SUSPENDED

Status

375

Enrollment

INDUSTRY

Sponsor class

Stopped FSI delayed until 15 January 2013

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin
DRUG: Dapagliflozin
DRUG: placebo

Sponsor

AstraZeneca

Collaborators

[object Object]